In contrast, PPARγ agonists restored CD8+ Teffs pools, potentiated vaccine-driven anti-tumor response in combination with CTLA4 Ab in vivo, and reduced chemokine expression in tumor cell co-cultures with human peripheral blood mononuclear cells in vitro. The gene discussed is CD8A; the disease is neoplasm.